89bio Inc

NASDAQ:ETNB  
27.55
+0.51 (+1.89%)
Other Pre-Announcement

89Bio Inc - Topline Results From Bio89-100'S Phase 2 Shtg Trial Expected In 2H21

Published: 11/10/2020 21:34 GMT
89bio, Inc. (ETNB) - 89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Topline Results From Bio89-100's Phase 2 Shtg Trial Expected in 2h21.
Qtrly Loss per Share $0.86.
Q3 Earnings per Share View $-0.84 -- Refinitiv Ibes Data (analyst estimates).
Topline Results From Bio89-100's Phase 2 Shtg Trial Expected in 2h21.
Updated Clinical Data From Bio89-100's Phase 1b/2a Nash Trial to Be Presented As a Late-breaking Poster at Upcoming Aasld Liver Meeting.